Alignment Healthcare (ALHC)

• Market cap: $2.05B
• 1 day: 0.09%
• 5 days: -1.74%
• 1 month: -13.48%
• 3 months: -2.99%
• 6 months: 41.42%
• Year to date: 26.27%
• 1 year: 23.22%
• 5 years: -38.07%
• 10 years: -38.07%
• Sector: Financials
• Industry: Hospital & Medical Service Plans

About: Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.

Employees: 1,536

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

150% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 12

83% more call options, than puts

Call options by funds: $255K | Put options by funds: $139K

49% more capital invested

Capital invested by funds: $1.32B [Q2] → $1.97B (+$650M) [Q3]

15% more funds holding

Funds holding: 118 [Q2] → 136 (+18) [Q3]

5% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 42

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

1.1% less ownership

Funds ownership: 88.04% [Q2] → 86.94% (-1.1%) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $8 25% downside
• Avg. target: $12.50 17% upside
• High target: $17 59% upside

4 analyst ratings

• positive: 2 50%
• neutral: 1 25%
• negative: 1 25%

Stephens & Co. Scott Fidel 49% 1-year accuracy 21 / 43 met price target	59% upside $17	Overweight Upgraded	3 Dec 2024
TD Cowen Gary Taylor 21% 1-year accuracy 4 / 19 met price target	21% upside $13	Buy Maintained	31 Oct 2024
Barclays Andrew Mok 29% 1-year accuracy 18 / 62 met price target	25% downside $8	Underweight Maintained	30 Oct 2024
UBS Kevin Caliendo 56% 1-year accuracy 9 / 16 met price target	12% upside $12	Neutral Maintained	30 Oct 2024